Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTeam17 Regulatory News (TM17)

  • There is currently no data for TM17

Trading Update

24 Nov 2023 07:00

RNS Number : 5304U
Team17 Group PLC
24 November 2023
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

24 November 2023

 

Team17 Group plc

("Team17" or the "Group" or "Company")

 

Trading Update

 

Team17 Group plc (the "Group"), a global games label, creative partner, developer and publisher of independent ("indie") premium video games, educational entertainment apps for children, and working simulation games, today announces a trading update and an updated outlook for the current financial year ending 31 December 2023.

 

FY23 outlook

 

While the important trading periods of Black Friday and Christmas are not yet complete, management believes the Group remains well positioned with strong traction across its new release and back catalogue titles, and currently expects FY23 revenues to be modestly ahead of current market expectations.

 

Despite this overall robust revenue performance, certain titles within the Games Label are not meeting internal expectations, resulting in a less favourable mix between higher margin own-IP titles and third-party titles (with higher royalty payments) than anticipated. In addition, the Group was too slow to address some project overspends and has faced some delays in implementing key cost initiatives at Team 17 Games Label. These are now at advanced stages and will continue to bring benefits into next year.

 

Management continues to be pleased with the performance of astragon and StoryToys. However, since the H1 results, and in the light of the post Covid-19 dynamics, management has re-evaluated the cost structure within Team17 Games Label to align with its core competencies as an indie game developer and publisher. In addition, it is also reviewing a number of titles, both under development and already launched, to assess the revenue potential in the current market environment, which is expected to result in impairments recognised in FY23.

 

Consequently, the Group now expects to deliver full year adjusted EBITDA of at least £28.5m, which includes non-cash title impairments of up to £11.5m.

 

FY24 outlook

 

The Group has an exciting schedule of high-quality new releases planned across the Group in 2024, while back catalogue investments will continue to support revenue growth. Management will provide greater clarity on FY24 at the full year results, but currently expects to see an improved underlying trading performance compared to FY23.

 

 

Enquiries:

 

Team17 Group plc

Debbie Bestwick MBE, Chief Executive Officer

Steve Bell, Chief Executive Officer Designate

Mark Crawford, Chief Financial Officer

James Targett, Group Investor Relations Director

 

via Vigo Consulting

 

Houlihan Lokey UK Limited (Nominated Adviser)

Adrian Reed / Tim Richardson

 

+44 (0)161 250 3577

Berenberg (Joint Corporate Broker)

Toby Flaux / Ben Wright / Marie Moy / Alix Mecklenburg-Solodkoff

 

+44 (0)20 3207 7800

Peel Hunt (Joint Corporate Broker)

Neil Patel / Paul Gillam / Richard Chambers / James Smith

 

+44 (0)20 7418 8900

Vigo Consulting (Financial Public Relations)

Jeremy Garcia / Fiona Hetherington / Aisling Fitzgerald

team17@vigoconsulting.com

+44 (0)20 7390 0233

 

 

About Team17

Team17 Group plc is a global provider of games entertainment to a broad audience. The Group now includes a games entertainment label and creative partner for indie developers, a leading developer of educational apps, targeting children under the age of eight, and a leading working simulation games developer and publisher.

 

Visit www.team17.com for more info.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBJBLTMTJTBAJ
Date   Source Headline
23rd Jan 20257:00 amRNSTrading Update and Change of Company Name
15th Nov 202412:30 pmRNSIssue of Shares and Total Voting Rights
15th Nov 202410:00 amRNSEstablishment of New Option Plan, Grant of Options
7th Nov 20243:33 pmRNSDirector Dealing
6th Nov 20247:00 amRNSChange of Nomad & Directors Disclosures
1st Nov 20247:00 amRNSHoldings in Company
30th Oct 20247:00 amRNSBoard Change
24th Oct 20244:20 pmRNSHoldings in Company
14th Oct 20247:00 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSChange of Nominated Advisor
17th Sep 20247:00 amRNSHalf Year Results
11th Sep 20243:02 pmRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSHoldings in Company
4th Sep 20242:25 pmRNSHoldings in Company
28th Aug 20247:00 amRNSNotice of Results & Analyst/Investor Presentations
22nd Aug 20247:00 amRNSHoldings in Company
14th Aug 20244:15 pmRNSDirector/PDMR Shareholding
17th Jul 20247:00 amRNSTrading Update
11th Jul 20245:03 pmRNSDirector/PDMR Shareholding
9th Jul 20244:18 pmRNSDirector/PDMR Shareholding
19th Jun 202411:15 amRNSResult of AGM
13th Jun 20249:20 amRNSDirector/PDMR Shareholding
3rd Jun 20247:00 amRNSAppointment of Joint Corporate Broker
23rd May 202412:00 pmRNSPosting of Annual Report and Notice of AGM
13th May 20244:55 pmRNSDirector/PDMR Shareholding
16th Apr 20247:00 amRNSUnaudited Final Results 2023
12th Apr 20241:16 pmRNSDirector/PDMR Shareholding
11th Apr 20247:00 amRNSNotice of Analyst & Investor Meetings, FY Results
19th Mar 20243:29 pmRNSHoldings in Company
13th Mar 20248:30 amRNSDirector/PDMR Shareholding
1st Mar 20248:58 amRNSNotice of Results
14th Feb 20241:00 pmRNSDirector/PDMR Shareholding
13th Feb 20244:28 pmRNSDirector/PDMR Shareholding
1st Feb 20241:10 pmRNSHolding(s) in Company
29th Jan 20247:00 amRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading Update
19th Jan 20243:01 pmRNSHolding(s) in Company
12th Jan 20244:53 pmRNSHolding(s) in Company
12th Jan 20243:04 pmRNSHolding(s) in Company
11th Jan 20243:23 pmRNSDirector/PDMR Shareholding
14th Dec 20239:15 amRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSDirector Dealings
27th Nov 20237:00 amRNSDirector Dealings
24th Nov 20237:00 amRNSTrading Update
15th Nov 20233:29 pmRNSHolding(s) in Company
13th Nov 20234:57 pmRNSDirector/PDMR Shareholding
30th Oct 20233:51 pmRNSHolding(s) in Company
18th Oct 202312:41 pmRNSHolding(s) in Company
11th Oct 20235:14 pmRNSDirector/PDMR Shareholding
21st Sep 20231:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.